Photo CREDIT: ISTOCK.com/OLGA ARKHIPENKO
Researchers Found that a nutracetical combining pollen extract and tepolioside effectivel alleviated Lower Urinary tract symptoms in patients with bph.
The Nutracetical Combining Pollen Extract and Tepolioside Alleviated Lower Urinary Tract Symptoms (Luts) Safely and Effectively in Men with Benign Prostatic Hyperplasia (BPH), According to Study Published Online in Archivio Italian Di Urology and Andrology.
The Product, Xipag (IDI Integratori Dietetici Italiani SRL), is designated to target infmmation and reduce diydrotastosterone production.
“The Precivious Documentated in the Literature, The Effectiveness of Tepolioside in Addressing Prostatic Hypertrophy and That of Pollen Extract in Alleviating SchpToms as Chronic Pelvic Pain and irritation are well stablished, Making this Product Private Promising Promising for Managing Moderate Luts, ”Study Author MATTIA LO RE, MDof Careggi University Hospitaland coauthors NOTED.
Testing The Promise
The Researchers Drived a Single-Center Observational Study Assessing its Effectiveness in Improving Urinary Function and Symptles in Men with Mil to Moderate Luts.
SIXTY PATIES WITH BPH WERE ENROLLLED AND REIVED ONE TABLET OF Xipag Daily for Three Months. Participants Were Evaluated at Baseline, One Month, and Three Months Using Three Validated Questionnaires: The International Prostate Sympton Score (IPSS), The Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form, and the International Index of Erectile Function. Assessments Included Blood Dows for Prostate-Specific Antigen (PSA) Levels and Uroflowmetry with Post-Void Residual (PVR) Measterment.
Significant Symptom Improvement
Of the 60 Patients, 53 Completed Follow-up Assessments. Statisically Significant Improvements in Urinary Sympton Were Observed: Between Baseline and Month 3, IPSS Scores Decreated from 14 to 10, While Ipss Qol Scores Improved from 3 to 2. Although Not Statistically Significant, Objective Urinary Flow Metrics Showed Favorable Trends: Maximum Flow Rate (qmax) Increassed from 12 ml/s to 15 ml/s, and pvr volume declined from 50 ml to 35 ml. Sexual Function and PSA Levels Remained Largely Stable Throughout the Study. At Serious Adverse Events Were Reported.
“After 3 Months of Treatment, 44 patients (83.2%) Expressed Their Willingness to Continue. Three Patients (5.7%) Reported in significant improvement in luts and expressed the desire to switch to another therapy,” The Researchers wrote. ADDITIONALLY, SIX PATENTS (11.3%) with MILD LUTS DISCONTINUED THE PRODUCT BUT REMAINED OPEN TO FUTURE USE IF SYMPTOMS PROGRESSED.
“The size of our cohort enables a more robust analysis and provides valuable date to the Limited literature on xipag,” researchers concluded, “and contributes to the grewing body of evidence supporting the use of nutraceticals in managing bph-relassed sympts, particularly in case Where Conventional Therapies May Lead To Undesirable Side Effects. ”
